Sinopharm Group
Market Cap
HK$77.5b
Last Updated
2019/10/23 12:48 UTC
Data Sources
Company Financials +
Executive Summary
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China.
Snowflake
Fundamentals
Established dividend payer and fair value.
Similar Companies
Share Price & News
How has Sinopharm Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-1.5%
1099
0.8%
HK Healthcare
0.3%
HK Market
1 Year Return
-29.5%
1099
-25.2%
HK Healthcare
1.3%
HK Market
Return vs Industry: 1099 underperformed the Hong Kong Healthcare industry which returned -25.2% over the past year.
Return vs Market: 1099 underperformed the Hong Kong Market which returned 1.3% over the past year.
Shareholder returns
| 1099 | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.5% | 0.8% | 0.3% |
| 30 Day | -5.7% | -0.7% | 0.5% |
| 90 Day | -15.1% | -2.8% | -4.6% |
| 1 Year | -27.8%-29.5% | -23.6%-25.2% | 4.9%1.3% |
| 3 Year | -27.2%-31.7% | -32.4%-36.5% | 15.3%3.7% |
| 5 Year | -5.9%-13.8% | -31.2%-37.3% | 20.0%-0.006% |
Price Volatility Vs. Market
How volatile is Sinopharm Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Should Sinopharm Group Co. Ltd. (HKG:1099) Be Part Of Your Dividend Portfolio?2 weeks ago | Simply Wall St
What Kind Of Shareholder Owns Most Sinopharm Group Co. Ltd. (HKG:1099) Stock?3 weeks ago | Simply Wall St
Read This Before You Buy Sinopharm Group Co. Ltd. (HKG:1099) Because Of Its P/E RatioValuation
Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?
33.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1099 (HK$25.65) is trading below our estimate of fair value (HK$38.49)
Significantly Below Fair Value: 1099 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 1099 is good value based on its PE Ratio (11.4x) compared to the Healthcare industry average (16.6x).
PE vs Market: 1099 is poor value based on its PE Ratio (11.4x) compared to the Hong Kong market (10.3x).
Price to Earnings Growth Ratio
PEG Ratio: 1099 is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: 1099 is overvalued based on its PB Ratio (1.6x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
14.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1099's forecast earnings growth (14.1% per year) is above the savings rate (2%).
Earnings vs Market: 1099's earnings (14.1% per year) are forecast to grow faster than the Hong Kong market (11.1% per year).
High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1099's revenue (10.9% per year) is forecast to grow faster than the Hong Kong market (10% per year).
High Growth Revenue: 1099's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (14.4%).
Next Steps
Past Performance
How has Sinopharm Group performed over the past 5 years?
16.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 1099's earnings have grown by 16.4% per year over the past 5 years.
Accelerating Growth: 1099's earnings growth over the past year (7.2%) is below its 5-year average (16.4% per year).
Earnings vs Industry: 1099 earnings growth over the past year (7.2%) exceeded the Healthcare industry 5.6%.
Return on Equity
High ROE: 1099's Return on Equity (13.9%) is considered low.
Return on Assets
ROA vs Industry: 1099's Return on Assets is below or equal to the Healthcare industry average last year.
Return on Capital Employed
ROCE Improving: 1099 has improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Sinopharm Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥237.3B) exceeds its short term liabilities (CN¥191.7B)
Long Term Liabilities: 1099's short term assets (237.3B) exceeds its long term liabilities (11.2B)
Debt to Equity History and Analysis
Debt Level: 1099's debt to equity ratio (97.2%) is considered high
Reducing Debt: 1099's debt to equity ratio has increased from 87.9% to 97.2% over the past 5 years.
Debt Coverage: 1099's debt is not well covered by operating cash flow (2.5%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (4.2x coverage).
Balance Sheet
Inventory Level: 1099 has a high level of physical assets or inventory.
Debt Coverage by Assets: 1099's debt is covered by short term assets (assets are 3.405160x debt).
Next Steps
Dividend
What is Sinopharm Group's current dividend yield, its reliability and sustainability?
2.55%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 1099's dividend (2.55%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.26%).
High Dividend: 1099's dividend (2.55%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.18%).
Stable Dividend: 1099's dividends per share have been stable in the past 10 years.
Growing Dividend: 1099's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.1%), 1099's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1099's dividends in 3 years are forecast to be well covered by earnings (29.2% payout ratio).
Next Steps
Management
What is the CEO of Sinopharm Group's salary, the management and board of directors tenure and is there insider trading?
8.2yrs
Average management tenure
CEO
Yong Liu (50yo)
1.9yrs
Tenure
CN¥7,918,000
Compensation
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm ...
CEO Compensation Analysis
Compensation vs. Market: Yong has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Hong Kong market.
Compensation vs Earnings: Yong's compensation has increased by more than 20% in the past year.
Management Age and Tenure
8.2yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 1099's management team is seasoned and experienced (8.2 years average tenure).
Board Age and Tenure
5.1yrs
Average Tenure
52yo
Average Age
Experienced Board: 1099's board of directors are considered experienced (5.1 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 1,870,100 |
| Max Price | CN¥27.52 |
| Entity | Company |
| Shares | 22,558,700 |
| Max Price | CN¥28.12 |
| Entity | Company |
| Shares | 513,202 |
| Max Price | CN¥29.50 |
| Entity | Company |
| Shares | 737,200 |
| Max Price | CN¥29.18 |
| Entity | Company |
| Shares | 2,905,415 |
| Max Price | CN¥29.08 |
| Entity | Company |
| Shares | 2,337,467 |
| Max Price | CN¥29.92 |
| Entity | Company |
| Shares | 840,478 |
| Max Price | CN¥30.25 |
| Entity | Company |
| Shares | 812,258 |
| Max Price | CN¥33.12 |
| Entity | Company |
| Shares | 5,313,200 |
| Max Price | CN¥32.98 |
| Entity | Company |
| Shares | 1,723,087 |
| Max Price | CN¥32.63 |
| Entity | Company |
| Shares | 5,539,200 |
| Max Price | CN¥31.73 |
| Entity | Company |
| Shares | 332,800 |
| Max Price | CN¥34.24 |
| Entity | Company |
| Shares | 1,550,000 |
| Max Price | CN¥34.18 |
| Entity | Company |
| Shares | 1,814,043 |
| Max Price | CN¥34.98 |
| Entity | Company |
| Shares | 18,400 |
| Max Price | CN¥36.05 |
| Entity | Company |
| Shares | 3,565 |
| Max Price | CN¥36.05 |
| Entity | Company |
| Shares | 926,368 |
| Max Price | CN¥36.05 |
| Entity | Company |
| Shares | 2,795,056 |
| Max Price | CN¥36.05 |
| Entity | Company |
| Shares | 1,109,200 |
| Max Price | CN¥33.09 |
| Entity | Company |
| Shares | 1,214,000 |
| Max Price | CN¥34.97 |
Ownership Breakdown
Management Team
Wei Liu (61yo)
Joint Company Secretary
- Tenure: 8.2yrs
Robert Li (53yo)
Vice President
- Tenure: 1.8yrs
Yong Liu (50yo)
President & Executive Director
- Tenure: 1.9yrs
- Compensation: CN¥7.92m
Wanyong Lian (48yo)
Vice President
- Tenure: 0yrs
Zhiming Li (56yo)
Chairman
- Tenure: 2.6yrs
- Compensation: CN¥10.94m
Shuangjun Xu (50yo)
Non-Executive Vice President
- Tenure: 8.6yrs
Xiuchang Jiang (55yo)
CFO & Vice President
- Tenure: 9.4yrs
Wanjun Ma (50yo)
Vice President
- Tenure: 9.1yrs
Yijian Wu (49yo)
Company Secretary
- Tenure: 0.8yrs
Qingming Yu (55yo)
Executive Director
- Tenure: 1.3yrs
- Compensation: CN¥15.89m
Board Members
Fang Yao (50yo)
Chairman of Supervisory Committee
- Tenure: 8.8yrs
Qiyu Chen (47yo)
Vice Chairman
- Tenure: 5.9yrs
Yong Liu (50yo)
President & Executive Director
- Tenure: 1.9yrs
- Compensation: CN¥7.92m
Jindong Deng (54yo)
Non-Executive Director
- Tenure: 12.2yrs
Wee Seng Tan (63yo)
Independent Non-Executive Director
- Tenure: 5.1yrs
- Compensation: CN¥300.00k
Zhiming Li (56yo)
Chairman
- Tenure: 2.6yrs
- Compensation: CN¥10.94m
Hailson Yu (63yo)
Independent Non-Executive Director
- Tenure: 5.1yrs
- Compensation: CN¥300.00k
Zhengdong Liu (49yo)
Independent Non-Executive Director
- Tenure: 5.1yrs
Zhengdong Liu (49yo)
Independent Non-Executive Director
- Tenure: 5.1yrs
- Compensation: CN¥300.00k
Qingming Yu (55yo)
Executive Director
- Tenure: 1.3yrs
- Compensation: CN¥15.89m
Company Information
Sinopharm Group Co. Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sinopharm Group Co. Ltd.
- Ticker: 1099
- Exchange: SEHK
- Founded: 2003
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: HK$77.455b
- Shares outstanding: 2.97b
- Website: https://www.sinopharmgroup.com.cn
Number of Employees
Location
- Sinopharm Group Co. Ltd.
- Sinopharm Plaza
- No. 1001 Zhongshan Road (West)
- Shanghai
- 200051
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1099 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| SHTD.F | OTCPK (Pink Sheets LLC) | Yes | Foreign Shares-Foreign Listed | US | USD | Sep 2009 |
| X2S | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Sep 2009 |
| 1099 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| 1099 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Sep 2009 |
| SHTD.Y | OTCPK (Pink Sheets LLC) | ADR | US | USD | Aug 2012 |
Biography
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution se ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 12:48 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.